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Aim: The aim of this study is to investigate the effects of miR150 transfection on NK-like cells differentiated from adipose 
tissue derived mesenchymal stem cells (AD-MSCs). Methods: NK-like cells were differentiated from AD-MSCs and activated 
by miR150 transfection. Transfected/non-transfected NK-like cells were characterized by immunohistochemical and RT-
PCR analyzes. Apoptotic efficiency of the transfected/non-transfected NK-like cells on pancreatic cancer cells PANC1 were 
determined by TUNEL and RT-PCR. Results: In miR150-transfected cells, the increased expression of NK cell-specific 
genes such as GZMB, KIR2DL2, CD16, CD56, NKG2D, NKp46 and increased immunoreactivity of NK cell-specific surface 
marker CD314 (NKG2D) were evident. TUNEL assays showed that NK-like cells with/without transfection induced apoptosis 
in PANC1 cells in the same manner. The decrease in oncogene expression and the increase in the tumor suppressor gene 
expression in PANC1 cells upon co-culture with NK-like cells differentiated from AD-MSCs were more prominent follow-
ing miRNA150 transfection. Conclusion: It was shown in vitro that NK-like cells could be obtained by differentiation from 
AD-MSCs and their efficiency could be increased via miR150 transfection. The results are encouraging for further clinical 
studies in improvement of immunotherapeutic approaches for cancer therapy.
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Pancreatic cancer (PaCa) is currently the third 
most frequent cause of cancer-related death in the 
United States [1]. Pancreatic ductal adenocarcinoma 
(PDAC), the major histological subtype comprising 
90% of all PaCa, displays local invasion and metasta-
sis during early stages of the disease via developing 
intrinsic resistance to most therapeutics, contributing 
to its notoriously poor prognosis with 1–5% of 5-year 
survival rates (~6 months of median survival duration 
with currently available therapies) [2–4].
Natural killer (NK) cells constitute a significant com-
ponent of the innate immune system which contributes 
particularly to the anti-tumor immune response [5, 6]. 
NK cells recognize virus-infected and transformed ma-
lignant cells and then kill these target cells without prior 
sensitization [6, 7]. NK cells have various surface recep-
tors (NK cells are CD3-negative, CD16- and/or CD56-
positive) and cytotoxic granules. NK cells recognize 
tumor cells and are thought to be good candidates for 
adaptive immunotherapy against cancer [8]. Recently, 
they gained attention for their spontaneous cytotoxic-
ity against a broad range of malignancies and for their 
potential to become a “multi-purpose” anti-cancer 
agent and studies are focused on isolating and expand-
ing NK cells abundantly [1, 6, 8]. NK cells exist in the 
peripheral blood at a very low concentration and after 
isolation there is a need to expand them in culture in order 
to reach a sufficient concentration for clinical applica-
tions. However, prolonged culture leads to exhaustion 
of NK cells and they become ineffective in killing target 
cells and die within a few days in clinical applications. 
Therefore, in recent years there have been great interests 
in attempts to generate NK cells from more abundant cell 
sources. Until today, NK cells have been differentiated 
in vitro from different cell sources such as embryonic 
stem cells (ESCs) or hematopoietic stem cells (HSCs) [6]. 
NK cells have been also directly isolated from umbilical 
cord blood or peripheral blood cells [6, 9]. Mesenchymal 
stem cells (MSCs) are multipotent stem cells with promis-
ing potential for cancer research [10–12]. Recently, these 
cells draw attention because of their importance for tissue 
microenvironment and their ability of suppressing immune 
system [11]. They can be obtained from many tissues 
such as bone marrow and adipose tissue, etc. and are 
able to be proliferated or differentiated suitably in in vitro 
conditions [13, 14]. Usually adipose tissue can be ob-
tained easily and abundantly by a surgical procedure, 
which is not severely invasive and provides a rich source 
of MSCs [15, 16]. In addition, adipose derived MSCs 
(AD-MSCs) have less ethical problems when compared 
with other sources.
MicroRNAs (miRNAs) are short (~22 nt) noncoding 
regulatory RNAs that function as post-transcriptional 
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repressors of protein-coding target messenger RNAs 
and regulate translational repression or degrada-
tion [17, 18]. miR150 is expressed in various immune 
cells such as mature NK and innate NK T cells, B and 
T cells and is up-regulated during cellular matura-
tion [19]. Particularly miR150 is responsible for the 
development and activation of NK cells and regulates 
the production of IFNγ by NK cells [19].
The aim of this study is to differentiate AD-MSCs 
to NK-like cells by using miRNA transfection in ad-
dition to classical differentiation protocol and then 
to investigate the effect of these cells on human PaCa 
cells in vitro.
MATERIALS AND METHODS
Cell culture. AD-MSCs purchased from ATCC 
were cultured in MesenPRO (Thermo Fisher Scientif-
ic, MA, USA) medium. Human pancreatic duct endo-
thelial cells (hTERT HPDE) (a kind gift of MD Anderson 
Cancer Center, TX, USA) were cultured in keratinocyte 
serum free medium (Thermo Fisher Scientific, MA, 
USA) supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine, 10 ng/ml of endothelial 
growth factor and 1% penicillin/streptomycin (P/S) 
(BI, Cromwell, CT, USA). Human PaCa cell line 
(Panc1) was obtained from MD Anderson Cancer 
Center, TX, USA and cultured in DMEM medium 
supplemented with 10% FBS, 2 mM L-glutamine 
and 1% P/S. AD-MSC derived NK-like cells were 
cultured in RPMI-1640 medium supplemented with 
10% FBS, 12.5 ng/ml IL-2, 5 ng/ml IL-15 (Sigma, 
USA) and 1% P/S.
Hematopoietic induction. AD-MSC were cul-
tured in Stemline Hematopoietic Stem Cell Expansion 
Medium (Sigma, USA) supplemented with 1% bovine 
serum albumin (BSA), 0.1 mM 2-mercaptoethanol, 
200 μg/ml of transferrin, 40 mg/ml of low-density lipo-
protein (LDL), 10 mg/ml of insulin, 10 ng/ml of throm-
bopoietin (TPO), 50 ng/ml of stem cell factor (SCF), 
50 ng/ml Flt3 ligand, 20 ng/ml of granulocyte-
macrophage-colony stimulating factor (GM-CSF), 
20 ng/ml IL-3, and 20 ng/ml IL-6 for one week 
(Sigma, USA). The incubation period lasted for one 
week while refreshing with the medium which was not 
supplemented with IL-6 and TPO on 3rd and 6th days.
NK cell differentiation. Hematopoietically in-
duced-AD-MSCs were cultured in RPMI-1640 medium 
supplemented with 50 ng/ml SCF, 50 ng/ml Flt-3 li-
gand, 12.5 ng/ml IL-2, 20 ng/ml IL-7, 40 ng/ml IL-15, 
2 mM L-glutamine, and 10% FBS. The incubation 
period lasted for 4 weeks via refreshing the medium 
every three days.
MiR150 transfection. At the end of the 4th week 
of culturing, AD-MSC-NK cells were transfected 
with miR150 (Sigma, USA) using a nanoparticle 
(Xfect) (Takara Bio Inc., USA). In this procedure, 
AD-MSC-NK cells were incubated with nanoparticle-
miRNA complex consisting of miRNA150 and trans-
fection polymer for 48 h at 37 °C according to Xfect 
kit protocol.
Reverse transcription-polymerase chain reac-
tion (RT-PCR). Total RNA was isolated from miR150-
transfected and non-transfected AD-MSC-NK cells 
and PANC1 cells before and after co-culturing using 
RNeasy Mini Kit (Qiagen, Hilden, Germany). Ex-
pression of NK cells-specific genes such as GZMB, 
KIR2DL2, CD16, CD56, NKG2D and NKp46 in NK-like 
cells and cancer-related genes such as KRas, TP53, 
CDKN2A, SMAD4, TGFBR2, ARID1A by RT-PCR 
in PaCa cells was analyzed (Roche, LightCycler 480 In-
strument, Basel, Switzerland). The primers used are 
given in Table.
Table. Primers used for RT-PCR
Gene Forward primer Reverse primer
GZMB 5'-GAAACGCTACTAACTA-
CAGG-3
5'-CCACTCAGCTAAGAGGT-3
KIR2DL2 5'-AGGGTTCTTCTTGCTGC-3' 5'-AGTGTCCTTAAACTTCCCT-3'
CD16 5'-CCCAAGCTTGGGGCC-
GCCACCATGTGGCAGCT-
GCTCCTCCCAACT-3'
5'-GGGATCCCCAGGTG-
GAAAGAATGATGAGAT-3'
CD56 5'-TTGTTTTTCCTGGGAACT-
GC-3'
5'-CCGGATCTGCAGGTAGTT-
GT-3'
NKG2D 5'-TTGACTACTGGACATCTTT-
GCTTTTG-3'
5'-GAATAATGAGTTTAG-
GAATACAGC-3'
NKp46 5�-GGCTGTGTCTGAGT-
CAGAG-3�
5�-GAGTTCATGTCCGGGAT-
GTAG-3'
KRAS 5-AAGGCCTGCTGAAAAT-
GACTG-3'
5'-CAAAGAATGGTCCTGCAC-
CAG-3'
TP53 5'-AACGGTACTCCGCCACC-3' 5'-CGTGTCACCGTCGTGGA-3'
CDKN2A 5�-AGAGGAGGGGCTGGCTG-
GTCA-3'
5�-CAGCGCCCGCACCTCCTC-
TA-3'
SMAD4 5'-TTCTAGGTGGCTGGTCG-
GAA-3'
5'-CAGGTGATACAACTC-
GTTCG-3'
TGFBR2 5'-TCCGGGAAGGCGCCGTC-
CGCT-3'
5'-CGACTGTCAAGCGCAGCG-
GAGAG-3'
ARID1A 5'-CTTCAACCTCAGT-
CAGCTCCCA-3’
5'- GGTCACCCACCT-
CATACTCCTTT-3'
Beta Actin 5'-GCACCACACCTTCTA-
CAATG-3'
5'-TGCTTGCTGATCCA-
CATCTG-3
Immunohistochemical analysis. The cells 
were fixed with 4% paraformaldehyde for 30 min 
and were washed two times with phosphate buffer 
saline (PBS). They were then incubated 10 min with 
0.1% Triton X-100 solution on ice for permeabiliza-
tion and 3% hydrogen peroxide (H2O2) was applied 
for 5 min after washing with PBS. They were then 
treated with blocking solution (Invitrogen, CA, USA) 
for an hour at room temperature and were incubated 
with primary antibody anti-hNKG2D (RD Systems, 
MN, USA) overnight at 4 °C. The samples were 
washed with PBS and incubated with biotinylated 
rabbit anti-mouse second antibody (Invitrogen, 
CA, USA) for 30 min. After washing with PBS 
streptavidin-hydrogen peroxidase (Invitrogen, CA, 
USA) was added for 30 min. In order to develop the 
immunohistochemical reaction, diaminobenzidine 
(DAB) (ScyTek, UT, USA) was applied for 5 min. 
After washing with PBS, slides were stained with 
Mayer’s hematoxylin and mounted with mounting 
medium. The intensity of immunolabeling was evalu-
ated by the two investigators in different times with 
light microscopy (BX40, Olympus, Tokyo, Japan). 
The immunoreactivities were considered as nega-
tive (-), weak (+), moderate (++) and strong (+++).
Co-culture. PANC1 cells were co-cultured with 
AD-MSC-NK cells using polycarbonate membrane 
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(Sigma, MO, USA) in a ratio of 1:2 (NK:PANC1). After 
incubation for 1 week, the number of dead cancer cells 
was determined via TUNEL assay.
TUNEL assay. The in situ apoptosis detection 
kit (ApopTag Plus Peroxidase In Situ Apoptosis De-
tection Kit, Millipore, MA, USA) was used. The cells 
were fixed with 4% paraformaldehyde for 30 min 
and were washed two times with PBS. They were 
then incubated 10 min with 0.1% Triton X-100 solu-
tion on ice for permeabilization and endogenous 
peroxidase activity was inhibited with 3% H2O2. The 
cells were then incubated with equilibration buffer for 
10–15 s and TdT-enzyme in a humidified atmosphere 
at 37 ˚C for 60 min. They were subsequently put into 
pre-warmed working strength stop/wash buffer 
at room temperature for 10 min and incubated with 
anti-streptavidin-peroxidase for 45 min. Each step 
was separated by careful washing in PBS. Staining 
was performed with DAB and counterstaining was 
performed in Mayer’s hematoxylin.
Statistical analysis. Statistical analysis of the 
data was performed using the Mann — Whitney U test 
using the SPSS 16 (Statistical Package for the Social 
Sciences) program. The statistical significance was 
evaluated, considering p < 0.05 level as statistically 
significant.
RESULTS
Hematopoietic induction and NK-like cell 
differentiation. AD-MSCs in culture were ob-
served as fusiform cells adherent to the plastic 
surface (Fig. 1, a). When cultured in hematopoietic 
induction medium for a week, AD-MSCs detached 
from plastic surface and became suspended after 
forming sphere clusters (Fig. 1, b). Hematopoi-
etically induced-AD-MSCs were then cultured 
in NK differentiation medium for 4 weeks in order 
to obtain NK-like cells and these cells were called 
AD-MSC-NK cells (Fig. 1, c).
Fig. 1. Characterization of AD-MSC: a — AD-MSC culture; b — 
hematopoietic induction; c — AD-MSC-NK cell culture
Characterization of cultured cells was performed 
immunohistochemically. Distributions of CD90 and 
CD314 (NKG2D) were assessed following 4 weeks 
of culturing of AD-MSCs and AD-MSC-NK cells (Fig. 2). 
CD90 immunoreactivity was very weakly positive 
(Fig. 2, e) while NKG2D (CD314) immunoreactivity was 
strongly positive in AD-MSC-NK cells (Fig. 2, f) at the 
30th day of culture. In control slides, negative staining 
for both CD90 and CD314 was detected (Fig. 2, a, b).
Following miR150 transfection of NK cells differenti-
ated from AD-MSC, NKG2D immunoreactivity was found 
to be strongly positive for miR150-AD-MSC-NK cells 
in comparison to non-transfected AD-MSC-NK cells 
(Fig. 3).
Fig. 3. Immunoreactivity of CD314 (NKG2D) in AD-MSC-NK cells 
non-transfected (a) and miR150-transfected (b)
Expression of NK cell specific genes such as GZMB, 
KIR2DL2, CD16, CD56, NKG2D and NKp46 signifi-
cantly increased in AD-MSC-NK cells (p < 0.05) when 
Fig. 2. Characterization of AD-MSC (a, c, e) and AD-MSC-NK 
(b, d, f) cells. Control staining (a, b), CD90 (c, d), CD314 (NK-
G2D) (e, f)
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compared to undifferentiated AD-MSC as the control 
group (Fig. 4) and following miR150 transfection, 
the expression of these genes was found to be even 
greater in the miR150-transfected AD-MSC-NK cells 
(miR150-AD-MSC-NK) than the non-transfected 
AD-MSC-NK cells (AD-MSC-NK) (Fig. 5).
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Fig. 4. Variations in gene expressions of GZMB, 
KIR2DL2, CD16, CD56, NKG2D and NKp46 genes in AD-
MSC-NK cells in comparison to AD-MSC as the control 
group (Mean ± Standard Deviation, Mann — Whitney 
U test was applied; *p < 0.05 (n = 3 for each group)
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Fig. 5. Variations in gene expressions of GZMB, KIR2DL2, 
CD16, CD56, NKG2D and NKp46 genes in miR150-trans-
fected AD-MSC-NK cells in comparison to non-transfected 
AD-MSC-NK cells as the control group (Mean ± Standard Deviation, 
Mann — Whitney U test was applied; *p < 0.05 (n = 3 for each group)
Induction of apoptosis in PANC1 cells after 
co-culturing with AD-MSC-NK cells. The TUNEL 
me thod based on detection of DNA strand breaks 
to identify apoptotic cells was used. According to our 
TUNEL assay results, AD-MSC-NK and miR150-AD-
MSC-NK were both able to kill PANC1 cancer cells 
(Fig. 6). TUNEL-positive cells were not detected 
in the control staining of PANC1 cells, whereas 11% 
of TUNEL-positive cells were observed in PANC1 cells 
after co-culturing with NK cells (Fig. 6, b). After 
miR150 transfection of NK cells, the percentage 
of TUNEL-positive cells was 8.8% in miR150-NK-
PANC1 co-culture (Fig. 6, d) but only 3.0% in miR150-
NK-hTERT co-culture (Fig. 6, f). Only 4% of TUNEL-
positive cells were found in PANC1-AD-MSC co-
culture (Fig. 6, h).
After PANC1 cel ls were co-cultured with 
AD-MSC-NK cells, the expression of KRAS oncogene 
significantly decreased (p < 0.05), while the expression 
of tumor suppressor genes such as P53, CDKN2A, 
TGFBR2, and ARID1A significantly increased (p < 0.05) 
in comparison with that in PANC1 cells before co-
culturing (Fig. 7). After miR150 transfection, expres-
sion of tumor suppressor genes further increased 
while the oncogene expression was further reduced 
in PANC1 cells co-cultured with the miR150-trans-
fected AD-MSC-NK cells in comparison to co-culture 
of PANC1 cells with non-transfected AD-MSC-NK cells 
(Fig. 8).
Fig. 6. TUNEL assay: a — control (PANC1); b — PANC1-NK co-cul-
ture; c — control (PANC1); d — PANC1-miR150-transfected NK co-
culture; e — control (hTERT-HPDE); f — hTERT-HPDE-miR150-trans-
fected NK co-culture; g — control (PANC1); h — PANC1-AD-MSC 
co-culture
DISCUSSION
PaCa, which is frequently seen in the elderly, 
is an aggressive progressing cancer with 5-year 
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survival rate being less than 5%. In recent years, 
the incidence of the disease has been increasing 
steadily and it is in the first place among cancer related 
deaths [20, 21]. Among the studies of PaCa, cell-
based immunotherapeutic approaches are the most 
interesting ones. NK cell-based immunotherapeutic 
approaches in PaCa have been investigated in phase 
studies in which NK cells isolated from the donors 
or the patient were used [22].
In our study, the expression of NK cell-specific 
genes such as GZMB, KIR2DL2, CD16, CD56, 
NKG2D, and NKp46 and immunoreactivity of NK cell-
specific surface marker CD314 (NKG2D) were evalu-
ated in NK-like cells before and after performing 
nanoparticle mediated miR150 transfection in AD-
MSC-NK cells. Both miR150-transfected and non-
transfected NK cells were co-cultured with PaCa 
cells (PANC1) in order to evaluate their efficiency 
in killing cancer cells and our results showed that 
miR150-transfected NK cells and non-transfected 
NK cells have similar apoptotic activities. However, 
RT-PCR results indicated that the decrease in gene 
expressions of oncogenes and the increase in the 
expression of tumor suppressor genes of PaCa 
were more prominent in co-culturing PaCa cells with 
miR150-transfected NK cells in comparison to that 
in co-culturing PaCa cells with non-transfected 
NK cells.
The results of the immunohistochemical analysis 
showed that CD314/NKG2D staining was strongly posi-
tive in miR150-NK and AD-MSC-NK cells compared 
to AD-MSCs. RT-PCR analysis indicated that GZMB, 
KIR2DL2, CD16, CD56, NKG2D, and NKp46 genes 
expressed in NK cells were found to be more potent 
in the miR150-transfected cells.
According to TUNEL results, both miR150-trans-
fected AD-MSC-NK and non-transfected AD-MSC-
NK-like cells were similarly effective in inducing apop-
totic death of PaCa cells. While cells gone to apoptosis 
can be analyzed by TUNEL assay, the pre-apoptotic 
cells cannot be analyzed by this assay so we per-
formed Annexin V in our continuing study and deter-
mined 30% of pre-apoptotic cells in Annexin V assay 
(data not given).
It should also be noted that there is another 
pathway leading to cell death named pyroptosis, 
which is a proinflammatory apoptosis pathway. 
It will also be valuable to evaluate the pyroptosis 
pathway in PANC1-NK cells co-culturing via adding 
caspase-1 analysis to the procedures already used 
in our study. IL-18, an inflammatory cytokine as-
sociated with NK-like cells, is active in the pathway 
of pyroptosis, via activating caspase-1, which is not 
effective in the known apoptosis pathway but is ef-
fective in pyroptosis [23].
MSCs are derived from tissues that contain 
a rich source for the surrounding connective tis-
sue. And thus AD-MSCs are promising immuno-
modulator stem cells which can be obtained easily 
and abundantly from several tissues, in particular 
by liposuction and lipectomy procedures [24, 25], 
and AD-MSCs do not carry any legal problems 
as it is an issue for ESC-based studies. Moreover, 
the cells are easily obtained by getting ethical per-
mission of donors who are subjected to lipectomy 
procedures voluntarily [26]. Allogeneic NK cells 
can be easily obtained via differentiation protocol 
following hematopoietic induction from AD-MSCs 
and also the efficiency of NK cells can be increased 
via miRNA transfection. With their high potential 
as a new immunotherapeutic source, such NK cells 
will then be available to be used for clinical pur-
poses in the future.
There are many miRNAs that are expressed 
in human and mouse NK cells [27]. miR150, which 
regulates the function of NK cells is highly exo-
genously expressed in resting NK cells in human and 
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Fig. 7. Variations in gene expressions of KRAS, P53, CDKN2A, 
TGFBR2, and ARID1A genes in PANC1 cells after co-cultured 
with AD-MSC-NK cells in comparison to the PANC1 cells before 
co-culturing as the control group (Mean ± Standard Deviation, 
Mann — Whitney U test was applied; *p < 0.05 statistical signifi-
cance (n = 3 for each group)
Fig. 8. Variations in gene expressions of KRAS, P53, CDKN2A, 
TGFBR2, and ARID1A genes in PANC1 cells after co-cultured 
with miR150-transfected AD-MSC-NK cells in comparison 
to the PANC1 cells after co-culturing with the non-transfected 
AD-MSC-NK cells as the control group (Mean ± Standard Devia-
tion, Mann — Whitney U test was applied; *p < 0.05 statistical 
significance (n = 3 for each group)
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mice [28]. In our study, NK-like cells differentiated 
from AD-MSCs were transfected with miR150 using 
nanoparticles for the first time. RT-PCR analyzes 
showed that in both non-transfected NK cells and 
miR150-transfected NK cells oncogene KRAS ex-
pression decreased, while expression of tumor sup-
pressor genes (P53, CDKN2A, TGFBR2, SMAD4 and 
ARID1A increased).
In a recent study, Joshi and colleagues investi-
gated the effect of miRNAs responsible for regulating 
activation and function of NK cells on melanoma can-
cer stem cells. In their study, NK cells isolated from 
the peripheral blood and then transfected with anti-
miR155 or anti-miR146 both showed antitumorigenic 
effect on melanoma cells and increased production 
of antitumorigenic factors released from NK cells such 
as INFγ and granzyme B [29]. In ano ther study, Bezman 
and colleagues demonstrated that mice with a targeted 
deletion of miR150 have an impaired, cell lineage — in-
trinsic defect in their ability to generate mature NK cells 
while miR150 transgene promotes the development 
of NK cells, with more mature phenotype and also more 
responsive to activation indicating that miR150 transfec-
tion enhances the function of NK cells [19]. In accor-
dance with these findings, in our study, it was shown that 
miR150 increased the expression of NK cell-specific 
genes as it was shown in Fig. 3 and 5.
The efficiency of NK cells derived from HCSs ob-
tained from fresh or frozen cord blood samples was 
investigated in cancer cell lines using three different 
culture systems developed by Spanholtz et al. Ac-
cording to their data, the most effective NK cells were 
obtained from frozen cord blood HSCs and these cells 
can be used in cancer treatment [30]. A study by Lu-
evano and his team supported these results. It has 
been reported that NK cells obtained from frozen cord 
blood HSCs were more effective [9].
Since the activity of NK cells in cancer patients 
diminishes or disappears with time, cytokines which 
have potential in activating NK cells such as IL-2, 
IL-12, IL-15, IL-18, IL-21 are systemically adminis-
tered to the patients in order to induce endogenous 
NK cells [31]. However, in these treatment approaches 
high doses of these cytokines are administered to the 
patients to strengthen and enumerate NK cells, and 
it is known that this high dose cytokine treatment has 
systemic toxic effects [32]. In our study, while obtain-
ing NK-like cells from AD-MSCs which has potential 
for allogeneic use, we used cytokines at concentra-
tions such as 50 ng/ml SCF, 50 ng/ml Flt-3 ligand, 
12.5 ng/ml IL-2, 20 ng/ml IL-7, 40 ng/ml IL-15 for 
4 weeks in vitro during the differentiation protocol. 
In our study, when performing differentiation protocol 
in vitro we used IL-2 and IL-15 at the nanogram levels 
which would not lead to systemic toxicity in the future 
even we will continue to use cytokines at low levels 
during in vivo studies.
Since PaCa is one of the most aggressive cancers, 
our results are promising in improving immunothera-
peutic approaches to cure malignancies. The results 
of this study are encouraging for further clinical studies 
in improvement of immunotherapeutic approaches 
for treatment.
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